Form 4/A for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-04-26 00:00:00 ET · period of report 2022-01-06 · accession 0000899243-23-011781 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DAI | 2023-04-26 | 2022-01-06 | AMLX | FRATES JAMES M | CFO | C - Cnv Deriv | $0.00 | +19.5K | 19.5K | New | $0 |
| DAI | 2023-04-26 | 2022-01-06 | AMLX | FRATES JAMES M | CFO | C - Cnv Deriv | $0.00 | -19.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-06 | C | A | 19,482 | $0.00 | 19,482 | I By Trust | — | — | (F1) Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. (F2) This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4. (F3) Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |
| 2 | Derivative | Series C-1 Preferred Stock | 2022-01-06 | C | D | 19,482 | $0.00 | 0 | I By Trust | — · — to — | 19,482 Common Stock | (F1) Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date. (F2) This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the "Original Form 4") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4. (F3) Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. |